Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 27, 2017

Transgene begins dosing in Phase I/IIa glioblastoma trial

Transgene has started dosing patients with recurrent glioblastoma in a Phase I/IIa clinical trial conducted to evaluate its oncolytic virus TG6002.

Transgene has started dosing patients with recurrent glioblastoma in a Phase I/IIa clinical trial conducted to evaluate its oncolytic virus TG6002.

Being developed as an intravenous formulation, TG6002 is said to have various functions and a dual mechanism of action to improve anti-tumour selectivity and activity.

TG6002 is designed to combine oncolysis by tumour-selective viral replication with local delivery through production of 5-FU chemotherapy agent in the tumour.

Additionally, the candidate is expected to trigger an immune response after spreading of the antigen due to breakdown of the cancer cells.

The open-label Phase I/IIa trial will investigate the safety and tolerability of different increasing doses of intravenous TG6002 combined with an oral non-cytotoxic pro-drug, flucytosine called 5-FC.

As TG6002 expresses Fcu1 gene in the targeted cancer cells, it would locally convert the 5-FC into 5-FU.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
“We have established that its replication induces immunogenic cell lysis and the local production of chemotherapy.”

The firm has started treatment at the La Pitié-Salpêtrière hospital, Greater Paris University Hospitals in Paris, France.

Transgene chief medical officer Maud Brandely said: “Based on our compelling preclinical data, we have established that its replication induces immunogenic cell lysis and the local production of chemotherapy.

“We are excited to see this novel immunotherapy with multiple modes of action enter the clinic and look forward to obtaining results that will allow further development of TG6002 in several solid tumours indications.”

The trial will include patients who have failed standard of care therapy and will monitor anti-tumour activity of TG6002.

Preliminary results from the Phase I/IIa trial are expected to be available in the second half of next year.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU